Compare PNFP & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNFP | CYTK |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | PNFP | CYTK |
|---|---|---|
| Price | $97.52 | $64.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 16 |
| Target Price | ★ $112.00 | $82.38 |
| AVG Volume (30 Days) | 1.5M | ★ 2.1M |
| Earning Date | 01-21-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ 49.26 | N/A |
| EPS | ★ 7.83 | N/A |
| Revenue | ★ $1,885,186,000.00 | $87,211,000.00 |
| Revenue This Year | $31.73 | $346.43 |
| Revenue Next Year | $128.60 | $57.69 |
| P/E Ratio | $12.39 | ★ N/A |
| Revenue Growth | 21.58 | ★ 2609.26 |
| 52 Week Low | $81.57 | $29.31 |
| 52 Week High | $127.85 | $70.98 |
| Indicator | PNFP | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 54.42 |
| Support Level | $92.16 | $58.85 |
| Resistance Level | $100.50 | $64.43 |
| Average True Range (ATR) | 2.54 | 2.86 |
| MACD | -0.80 | 0.02 |
| Stochastic Oscillator | 56.08 | 48.80 |
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.